Results 141 to 150 of about 113,185 (266)

Langerhans Cell Histiocytosis Associated With Chronic Myeloid Leukemia: A Pediatric Case Report. [PDF]

Cancer Rep (Hoboken)
Latifi A, Yousefian S.
europepmc   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

The importance of bone marrow biopsy for chronic myeloid leukemia classification-a case report. [PDF]

J Hematop
Gonçalves NV, Filho HLAS, de Magalhães Gomes JPC, Amarante GBD, de Oliveira GB, Lorand-Metze I, Pagnano KBB, Assis-Mendonça GR.   +7 more
europepmc   +1 more source

Before Guillain‐Barre Syndrome Is Attributed to a CMV Infection, the Diagnosis Must Be Confirmed and Other Causes Must Be Ruled Out

The Kaohsiung Journal of Medical Sciences, EarlyView.
Josef Finsterer
wiley   +1 more source

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink   +10 more
wiley   +1 more source

Chronic Myeloid Leukemia Masked by Massive Splenomegaly: Splenectomy as a Strategy in a Resource-Limited Setting. [PDF]

Cureus
Bun S.
europepmc   +1 more source

Chronic myeloid leukemia in India

Indian Journal of Medical and Paediatric Oncology, 2013
openaire   +3 more sources

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Kinase inhibition rewires the HLA-I immunopeptidome in chronic myeloid leukemia. [PDF]

iScience
Venafra V, Wahle M, Massacci G, Bica V, Chiusolo P, Mougiakakos D, Boettcher M, Fischer T, Perfetto L, Mann M, Sacco F.   +10 more
europepmc   +1 more source

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

VIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin, Galyna Bila, Ileana Manduteanu, Rostyslav Bilyy   +3 more
wiley   +1 more source